Cytokeratin 5 Antibody – 165Ho

Catalog: 716503

Clone: EP1601Y

Isotype: Rabbit IgG

Reactivity: Human*

Application: MIBI-FFPE

Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

IHC: CK5 staining of FFPE human tonsil

CK5-Ionpath-MIBI-staining-FFPE-human-tonsil

MIBI: CK5 antibody staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)

IHC: CK5 staining of FFPE human breast

CK5-Ionpath-MIBI-staining-FFPE-human-breast

MIBI: CK5 antibody staining (cyan) of FFPE human breast, counterstained with dsDNA (magenta)

Background: Cytokeratin 5 (CK5) is part of cytoplasmic immediate filaments that make up the cytoskeleton of basal epithelial/myoepithelial cells. CK5 expression serves as an important diagnostic, prognostic and predictive marker for a variety of cancers including basal-like breast carcinoma, ovarian carcinoma, lung carcinoma and urothelial carcinoma.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views. These results are pathologist verified.

Recommended Usage: Human FFPE: 1:100 dilution.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References
Silvia Mihaela Illie et al. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. Breast Cancer (Dove Med Press). 2018; 10: 177–194.

Corr BR et al. Cytokeratin 5-positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer. Int J Gynecol Cancer. 2015 Nov;25(9):1565-73.

* Conjugate tested on human tissue.

Download Technical Data Sheet

Cytokeratin 5 Antibody – 165Ho

We are using cookies on our website